Reported menorrhagia and treatment received prior to diagnosis with low VWF
| Menorrhagia . | LoVIC, n (% of all female enrollees) . |
|---|---|
| Total cohort | 120 |
| Self-reported menorrhagia | 107/120 (89.2) |
| Symptoms | |
| Changing pads/tampons >2 hourly | 92 (76.6) |
| Bleeding >7 d | 69 (57.5) |
| Clots and flooding | 104 (86.6) |
| Medical consultation | |
| Consultation | 73 (60.8) |
| Iron therapy | 39 (32.5) |
| Antifibrinolytic | 23 (19.2) |
| Hormonal therapy | 47 (39.2) |
| Combined hormonal and antifibrinolytics | 8 (6.6) |
| Intrauterine levonorgestrel-releasing device | 20 (16.7) |
| Dilatation and curettage | 23 (19.2) |
| Endometrial ablation | 5 (4.2) |
| Hysterectomy | 9 (7.5) |
| Treatment with desmopressin | 1 (0.8) |
| Treatment with plasma/platelets/factor concentrate | 0 |
| Red blood cell transfusion | 2 (1.7) |
| Hospital admission and emergency treatment | 2 (1.7) |
| Duration of symptoms | |
| Symptoms since menarche | 84 (70.0) |
| >2 d off school/work per year | 47 (39.2) |
| Menorrhagia >12 mo | 21 (17.5) |
| Menorrhagia . | LoVIC, n (% of all female enrollees) . |
|---|---|
| Total cohort | 120 |
| Self-reported menorrhagia | 107/120 (89.2) |
| Symptoms | |
| Changing pads/tampons >2 hourly | 92 (76.6) |
| Bleeding >7 d | 69 (57.5) |
| Clots and flooding | 104 (86.6) |
| Medical consultation | |
| Consultation | 73 (60.8) |
| Iron therapy | 39 (32.5) |
| Antifibrinolytic | 23 (19.2) |
| Hormonal therapy | 47 (39.2) |
| Combined hormonal and antifibrinolytics | 8 (6.6) |
| Intrauterine levonorgestrel-releasing device | 20 (16.7) |
| Dilatation and curettage | 23 (19.2) |
| Endometrial ablation | 5 (4.2) |
| Hysterectomy | 9 (7.5) |
| Treatment with desmopressin | 1 (0.8) |
| Treatment with plasma/platelets/factor concentrate | 0 |
| Red blood cell transfusion | 2 (1.7) |
| Hospital admission and emergency treatment | 2 (1.7) |
| Duration of symptoms | |
| Symptoms since menarche | 84 (70.0) |
| >2 d off school/work per year | 47 (39.2) |
| Menorrhagia >12 mo | 21 (17.5) |